{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-022572","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.224690+00:00","generated_at":"2026-06-17T17:12:16.012028+00:00","sec_items":["5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity Therapeutics announces 1-for-35 reverse stock split effective March 24, 2023","bullets":["Reverse split reduces outstanding shares from 34,294,582 to ~979,846; no change in authorized shares (750M).","Split effective at 4:05 p.m. ET on March 24, 2023; trading begins post-split on Nasdaq March 27 under symbol ALLR.","Purpose: to increase per-share price to meet Nasdaq minimum bid price requirement and support capital raising.","Fractional shares rounded up to nearest whole share; proportional adjustments to options, warrants, and exercise prices.","CUSIP changed to 016744203; board determined ratio after stockholder approval at special meeting on March 20, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-022572","json":"https://secwatch.observer/filing/0001213900-23-022572.json","markdown":"https://secwatch.observer/filing/0001213900-23-022572.md","text":"https://secwatch.observer/filing/0001213900-23-022572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023022572/0001213900-23-022572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023022572/ea175667-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T17:12:16.012028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06a0ecec3e0254fdfa7a6d8fdb7df7ad75dbe001","claim":"Allarity Therapeutics, Inc.: Effected a 1-for-35 reverse stock split of common stock via amendment to Certificate of Incorporation (effective 2023-03-24).","evidence_excerpt":"On March 23, 2023, the Company filed a Third Certificate of Amendment of Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-35 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 4:05 p.m. (New York time) on March 24, 2023 (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023022572/0001213900-23-022572-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-03-24"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}